# Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)

> **NCT01808313** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 134 (actual)

## Conditions studied

- Vascular Disease

## Interventions

- **DRUG:** ambrisentan

## Key facts

- **NCT ID:** NCT01808313
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-01
- **Primary completion:** 2014-08-15
- **Final completion:** 2014-08-15
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2017-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01808313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01808313, "Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01808313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*